Ülke: Tanzanya
Dil: İngilizce
Kaynak: Tanzania Medicinces & Medical Devices Authority
Esomeprazole Magnesium
Alkem Laboratories Limited, INDIA
Drugs for peptic ulcer and gastro-oesophageal refl
Esomeprazole Magnesium
40 mg
Tablets
East African (India) Overseas, INDIA
Physical description: Coloured, square shaped, biconvex, film coated tablets plain on both side; Local technical representative: Planet Pharmaceutical Limited (6099)
Registered/Compliant
2022-05-04
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT A) NAME OF PRODUCT : NULOC TABLETS 40 MG B) GENERIC NAME : ESOMEPRAZOLE GASTRO-RESISTANT TABLETS C) PHARMACEUTICAL FORM : Tablets D) COMPOSITION : EACH ENTERIC COATED TABLETS CONTAINS: Esomeprazole Magnesium USP Eq. to Esomeprazole 40 mg Excipients q.s. Colour: Brilliant Blue Lake & Titanium Dioxide USP 2. QUALITATIVE AND QUANTITATIVE COMPOSITION A. QUALITATIVE COMPOSITION EACH ENTERIC COATED TABLETS CONTAINS: Esomeprazole Magnesium USP Eq. to Esomeprazole 40 mg Excipients q.s. Colour: Brilliant Blue Lake & Titanium Dioxide USP B. QUANTITATIVE COMPOSITION SR . N O. ITEM CODE MATERIAL NAME SPEC QUANTITY (MG) / TABLET % FORMULA W/W THEORETICAL QUANTITY/ BATCH (KG) OVG. IN (%) STANDARD QUANTITY / BATCH (KG) DRY MIXING 01 R/1464 Esomeprazole Magnesium Trihydrate * USP 44.550 22.275 8.910 ….. 8.910 02 R/299 Corn Starch USP 35.000 17.500 7.000 …. 7.000 03 R/42 Microcrystalline Cellulose (101)** USP 31.250 15.625 6.250 ….. 6.250 04 R/360 Mannitol USP 25.000 12.500 5.000 ….. 5.000 BINDER (BINDER PREPARATION) 05 R/7 Polyvinyl Pyrrolidone K-30 USP 6.000 3.000 1.200 ….. 1.200 06 R/57 Isopropyl Alcohol USP ….. …. 14.200 ….. 14.200 3. PHARMACEUTICAL FORM Tablets Blue coloured, round, biconvex, enteric coated tablets having both side plain. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Esomeprazole Gastro-resistant tablets are indicated in adults for: GASTROESOPHAGEAL REFLUX DISEASE (GERD) - Treatment of erosive reflux esophagitis - Long-term management of patients with healed esophagitis to prevent relapse - Symptomatic treatment of gastroesophageal reflux disease (GERD) IN COMBINATION WITH APPROPRIATE ANTIBACTERIAL THERAPEUTIC REGIMENS FOR THE ERADICATION OF _HELICOBACTER PYLORI _AND - Healing of _Helicobacter pylori _associated duodenal ulcer and - Prevention of relapse of peptic ulcers in patients with _Helicobacter pylori _associated ulcers PATIENTS REQUIRING CONTINUED NSAID THERAPY - Healing of gastric ulcers associated with NSAID t Belgenin tamamını okuyun